Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Acumen Pharmaceuticals (ABOS)
NASDAQ:ABOS
RESEARCH TOOLSreports
Holding ABOS?
Track your performance easily
ABOS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.54 - $5.09
Previous CloseN/A
Volume101.31K
Average Volume (3M)374.43K
Market Cap
$93.72M
Enterprise Value-$21.36M
Total Cash (Recent Filing)$6.55M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.50
Next Earnings
Mar 31, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.37
Shares Outstanding60,079,777
10 Day Avg. Volume328,438
30 Day Avg. Volume374,434
Standard Deviation0.28
R-Squared0.00
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)20547.28
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.23
Enterprise Value/Revenue-4.27K
Enterprise Value/Gross Profit-4.27K
Enterprise Value/Ebitda0.30
Forecast
1Y Price Target
$13.50Price Target Upside738.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Acumen Pharmaceuticals News
PremiumCompany Announcements
Acumen Pharmaceuticals Advances Alzheimer’s Therapeutic
PremiumCompany Announcements
Acumen Pharma Reports Q3 2024, Highlights Alzheimer’s Focus
Ownership Overview
27.86% Insiders
10.97% Mutual Funds
42.23% Other Institutional Investors
12.96% Public Companies and Individual Investors
ABOS FAQ
What was Acumen Pharmaceuticals’s price range in the past 12 months?
Acumen Pharmaceuticals lowest stock price was $1.54 and its highest was $5.09 in the past 12 months.
What is Acumen Pharmaceuticals’s market cap?
Acumen Pharmaceuticals’s market cap is $93.72M.
When is Acumen Pharmaceuticals’s upcoming earnings report date?
Acumen Pharmaceuticals’s upcoming earnings report date is Mar 31, 2025 which is in 72 days.
How were Acumen Pharmaceuticals’s earnings last quarter?
Acumen Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.362 by -$0.138.
Is Acumen Pharmaceuticals overvalued?
According to Wall Street analysts Acumen Pharmaceuticals’s price is currently Undervalued.
Does Acumen Pharmaceuticals pay dividends?
Acumen Pharmaceuticals does not currently pay dividends.
What is Acumen Pharmaceuticals’s EPS estimate?
Acumen Pharmaceuticals’s EPS estimate is -0.49.
How many shares outstanding does Acumen Pharmaceuticals have?
Acumen Pharmaceuticals has 60,079,777 shares outstanding.
What happened to Acumen Pharmaceuticals’s price movement after its last earnings report?
Acumen Pharmaceuticals reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.362. Following the earnings report the stock price went down -16.77%.
Which hedge fund is a major shareholder of Acumen Pharmaceuticals?
Among the largest hedge funds holding Acumen Pharmaceuticals’s share is RA Capital Management. It holds Acumen Pharmaceuticals’s shares valued at 37M.
---
Acumen Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.50 (738.51% Upside)
$13.50 (738.51% Upside)
Blogger Sentiment
Bullish
ABOS Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.4%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.64%
12-Months-Change
Fundamentals
Return on Equity
-32.83%
Trailing 12-Months
Asset Growth
-6.77%
Trailing 12-Months
Company Description
Acumen Pharmaceuticals
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.
---
ABOS Company Deck
---
ABOS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with rapid progress in clinical trials, strong financial management, and strategic leadership appointments, although it acknowledges increased R&D expenses and a net loss.Read More>---
ABOS Stock 12 Month Forecast
Average Price Target
$13.50
▲(738.51% Upside)
Technical Analysis
Annovis Bio
―
AC Immune SA
―
Cassava Sciences
―
Anavex Life Sciences
―
Inmune Bio
―
Axsome Therapeutics
―
Best Analysts Covering ABOS
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-41.23%
reiterated a buy rating 2 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -41.23% per trade.
---